Market News & Trends
Entolimod May be a Promising Treatment Option for Many Solid Tumors
A collaborative team of researchers led by Alex A. Adjei, MD, PhD, FACP, of Roswell Park Cancer Institute (RPCI) shared results from the first clinical…
EMD Millipore to Acquire Exclusive Rights to Singulex's Technology
EMD Millipore and Singulex recently announced they have entered into a definitive agreement under which EMD Millipore will control and manage the Singulex Life Science…
Alligator Bioscience AB Phase I Trial Benefits From Cobra Biologics' maxXpress Platform
Cobra Biologics, an international CDMO of biologics and pharmaceuticals, has developed a cell line for Alligator Bioscience, a Swedish biotechnology company, expressing monoclonal antibodies for…
NanoString Announces Significant Clinical Research Collaboration
NanoString Technologies and Merck recently announced a clinical research collaboration to develop an assay that will optimize immune-related gene expression signatures and evaluate the potential…
IGI Laboratories Announces Third ANDA Submission of 2015
IGI Laboratories, Inc. recently announced it has submitted its third abbreviated new drug application (ANDA) to the US Food and Drug Administration (FDA) of 2015,…
Pharmaxis to Focus on Partnering; Sells Phase I Drug Candidate to Boehringer
Pharmaxis recently announced its transition to a strategic business plan with an increased focus on innovation and partnering in order to generate value. The new…
DURECT Corporation Announces Positive Study Results
DURECT Corporation recently announced it has obtained positive results from a multi-dose Phase I clinical trial with an oral formulation of DUR-928, the lead molecule…
Novozymes Biopharma Enables Stable Formulation of Serendex Pharmaceutical’s Drug
Denmark-based Serendex Pharmaceuticals recently announced they will initiate Phase I clinical trials for their Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) drug candidate, Molgradex. The drug…
Pluristem Announces Significant Advancement to its Clinical Development Plan
Pluristem Therapeutics Inc. (PSTI) recently announced a significant advancement to its clinical development plan: the PLX cell program in critical limb ischemia has been selected…
Eleven Biotherapeutics Announces Top-Line Results From Pivotal Phase III Study
Eleven Biotherapeutics, Inc. recently announced top-line results from the OASIS study, the company’s first pivotal Phase III study of its lead drug candidate, EBI-005, in…
First Patient Dosed in Phase II Study of Tipifarnib
Kura Oncology, Inc. recently announced that the first patient has been dosed in the Phase II clinical trial of tipifarnib in patients with locally advanced…
Meggle Introduces World’s First Triple Compound
Meggle recently announced the introduction of a new high-functionality excipient (HFE) CombiLac®, a lactose-based, co-processed excipient, specifically designed to ease oral solid dosage form development…
Cortendo Adds Two Late-Stage Assets & Announces Related $33.2 Million Financing
Cortendo AB recently announced it has entered into an agreement to acquire Aspireo Pharmaceuticals’ Somatoprim (DG3173), an investigational compound being studied for the treatment of…
Selecta Biosciences Makes Two Major Announcements
Selecta Biosciences, Inc. recently announced that, under the terms of an existing strategic global collaboration, Sanofi has exercised its option to an exclusive license to…
Pfizer Acquires Minority Interest in Biopharmaceutical Company; Secures Option to Acquire
AM-Pharma B.V. and Pfizer Inc. recently announced that Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the…
BASF to Focus Pharmaceutical Ingredients Business on its Core Expertise
BASF plans to focus its pharmaceutical ingredients and services business within the Nutrition & Health division on its core expertise in pharmaceutical excipients. To implement…
Lilly & Sanford-Burnham Announce Major Collaboration
Eli Lilly and Company and Sanford-Burnham Medical Research Institute recently announced they will collaborate to discover and develop immunological therapies. Lilly and Sanford-Burnham, a non-profit…
Strategic Product Lifecycle Management Through Secondary Packaging
Developing and launching a new drug is often a burden on resources, time and money. Pharmaceutical and biotech companies can only afford the…
bluebird bio Announces Global Regulatory Strategy for Gene Therapy
bluebird bio, Inc., a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, recently…
West Bolsters R&D Strategy With Global Site Expansions & Upgrades
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative packaging components and drug delivery systems, today announced a multi-year investment as part of…
